Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
BusinessWire - Fri Jun 7, 7:00AM CDT
BusinessWire - CMTX
Fri Jun 7, 7:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET).
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
BusinessWire - Fri May 17, 1:01PM CDT
BusinessWire - CMTX
Fri May 17, 1:01PM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo. These data supported the initiation of a Phase 1 program of mRNA-1944 against chikungunya virus in January 2019 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
BusinessWire - Fri May 10, 8:00AM CDT
BusinessWire - CMTX
Fri May 10, 8:00AM CDT
--Results are from Moderna's first human studies of mRNA vaccines; demonstrates a new technological approach to flu vaccine development and production
Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates
BusinessWire - Wed May 8, 6:00AM CDT
BusinessWire - CMTX
Wed May 8, 6:00AM CDT
--Immuno-Oncology: Two personalized cancer vaccine (PCV) abstracts to be presented at the 2019 ASCO Annual Meeting
Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference
BusinessWire - Mon May 6, 7:00AM CDT
BusinessWire - CMTX
Mon May 6, 7:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT (12:20 p.m. ET).
Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
BusinessWire - Mon Apr 29, 7:00AM CDT
BusinessWire - CMTX
Mon Apr 29, 7:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that it will present, along with academic collaborators, preclinical data from seven studies that support the potential of mRNA-based therapies to treat the underlying cause of several rare metabolic and genetic disorders. These data, including five oral presentations, will be presented at the 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place April 29 - May 2 in Washington, D.C.
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019
BusinessWire - Tue Apr 16, 7:00AM CDT
BusinessWire - CMTX
Tue Apr 16, 7:00AM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update.
Moderna to Present at 18th Annual Needham Healthcare Conference
BusinessWire - Wed Apr 3, 5:02PM CDT
BusinessWire - CMTX
Wed Apr 3, 5:02PM CDT
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced that Tal Zaks, M.D., Ph.D., Moderna's Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET.
Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress
BusinessWire - Wed Mar 6, 6:00AM CST
BusinessWire - CMTX
Wed Mar 6, 6:00AM CST
--Ends Year With $1.7 Billion in Cash, Cash Equivalents and Investments
Moderna to Present at Upcoming Investor Conferences in March
BusinessWire - Mon Mar 4, 4:30PM CST
BusinessWire - CMTX
Mon Mar 4, 4:30PM CST
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients,today announced its participation in the following upcoming investor conferences:

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).